Get the Stockscreener App
1.225
2.00%
-0.025
Celularity Inc stock is traded at $1.225, with a volume of 4,043.
It is down -2.00% in the last 24 hours and down -8.58% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$1.25
Open:
$1.22
24h Volume:
4,043
Relative Volume:
0.03
Market Cap:
$35.33M
Revenue:
$40.58M
Net Income/Loss:
$-80.65M
P/E Ratio:
-0.3678
EPS:
-3.331
Net Cash Flow:
$-8.11M
1W Performance:
-3.54%
1M Performance:
-8.58%
6M Performance:
-44.82%
1Y Performance:
-26.65%
1-Day Range:
$1.21
$1.225
1-Week Range:
$1.18
$1.34
52-Week Range:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.225 | 36.05M | 40.58M | -80.65M | -8.11M | -3.331 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.44 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.31 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.75 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.77 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.87 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
NEXGEL Inc and Celularity Inc License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - marketscreener.com
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
NexGel to Acquire Celularity Biomaterials Assets and Exclusive License in Deal Up to $35 Million - TradingView
Deal to triple NEXGEL (NASDAQ: NXGL) revenue and add profits - Stock Titan
Celularity Sells and Licenses Biomaterials Portfolio to NexGel in Deal Worth Up to $35 Million - TradingView
Celularity (Nasdaq: CELU) monetizes biomaterials in $35M license, pivots to longevity - Stock Titan
Biotechnology company Celularity Inc. recently announced a significant personnel change. - Bitget
NEXGEL, Inc. to Acquire Regenerative Biomaterial Portfolio from Celularity, Anticipating Tripled Revenue and Immediate Profitability - Quiver Quantitative
Biotechnology company Celularity Inc. (NASDAQ: CELU) has recently reached a strategic licensing agreement totaling 35 million dollars. - Bitget
NEXGEL Signs Definitive Agreement to License and Acquire - GlobeNewswire
Celularity Inc. Announces Strategic Partnership to Commercialize Biomaterials Portfolio, Generating Up to $35 Million in Payments - Quiver Quantitative
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
NEXGEL grabs Celularity biomaterials in move expected to turn a profit - Stock Titan
Celularity names John Sprague acting CFO following executive departure - Investing.com Nigeria
CELU SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Celularity Inc a defensive stockPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
Will Celularity Inc. stock reach all time highs in 2026Weekly Loss Report & Reliable Price Action Trade Plans - Naître et grandir
Take Profit: Is Celularity Inc Equity Warrant impacted by rising ratesJuly 2025 Price Swings & Stock Market Timing Techniques - baoquankhu1.vn
Aug Shorts: What is Celularity Inc Equity Warrants revenue forecastJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Celularity names John Sprague acting CFO following executive departure By Investing.com - Investing.com India
Joseph Dossantos, Acting CFO, Leaves Celularity On Feb 27, 2026SEC Filing - TradingView
Celularity Inc Announces Departure of Joseph Dossantos as Svp, Finance, Effective February 27, 2026 - marketscreener.com
Celularity Inc. Shares Seek Catalysts Amid Sector-Watch Phase () - aktiencheck.de
CELU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CELUW SEC FilingsCelularity Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CELUW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):